• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

BCL-2 Inhibitor and Conventional Chemotherapy Combinations for Acute Myeloid Leukemia: Shifting From the Unfit to the Fit Patient With AML.

作者信息

Ossenkoppele Gert, Vyas Paresh

机构信息

Department of Hematology, Amsterdam University Medical Centers, Location Vrije Universiteit University Medical Center, Amsterdam, the Netherlands.

Medical Research Council Molecular Haematology Unit, Biomedical Research Centre Haematology Theme, Oxford Biomedical Research Centre, Oxford Centre for Haematology, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford; and Department of Haematology, Oxford University Hospitals NHS Trust, Oxford, United Kingdom.

出版信息

J Clin Oncol. 2020 Oct 20;38(30):3461-3464. doi: 10.1200/JCO.20.01788. Epub 2020 Jul 30.

DOI:10.1200/JCO.20.01788
PMID:32730185
Abstract
摘要

相似文献

1
BCL-2 Inhibitor and Conventional Chemotherapy Combinations for Acute Myeloid Leukemia: Shifting From the Unfit to the Fit Patient With AML.用于急性髓系白血病的BCL-2抑制剂与传统化疗联合方案：从不适宜的急性髓系白血病患者转向适宜的患者。
J Clin Oncol. 2020 Oct 20;38(30):3461-3464. doi: 10.1200/JCO.20.01788. Epub 2020 Jul 30.
2
Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML.S100A8和S100A9的表达升高与急性髓系白血病（AML）对BCL-2抑制剂维奈托克的耐药性相关。
Leukemia. 2019 Oct;33(10):2548-2553. doi: 10.1038/s41375-019-0504-y. Epub 2019 Jun 7.
3
CD34 acute myeloid leukemia cells with low levels of reactive oxygen species show increased expression of stemness genes and can be targeted by the BCL2 inhibitor venetoclax.活性氧水平低的CD34急性髓系白血病细胞显示干性基因表达增加，并且可被BCL2抑制剂维奈托克靶向作用。
Haematologica. 2020 Aug;105(8):e399-e403. doi: 10.3324/haematol.2019.229997. Epub 2019 Nov 14.
4
Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations. Venetoclax 治疗后急性髓系白血病的复发和耐药：改善二线治疗和联合治疗。
Expert Rev Hematol. 2024 Oct;17(10):723-739. doi: 10.1080/17474086.2024.2402283. Epub 2024 Sep 13.
5
[Application of Bcl-2 inhibitor venetoclax in acute myeloid leukemia].Bcl-2抑制剂维奈托克在急性髓系白血病中的应用
Zhonghua Xue Ye Xue Za Zhi. 2021 May 14;42(5):438-440. doi: 10.3760/cma.j.issn.0253-2727.2021.05.018.
6
Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.联合 BH3 模拟物靶向 BCL-2 和 MCL1 在急性髓系白血病的临床前模型中具有强大的活性。
Leukemia. 2019 Apr;33(4):905-917. doi: 10.1038/s41375-018-0261-3. Epub 2018 Sep 10.
7
Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199.携带MLL融合基因或具有急性早幼粒细胞白血病表型的急性髓系白血病细胞对Bcl-2选择性抑制剂ABT-199敏感。
Leukemia. 2014 Jul;28(7):1557-60. doi: 10.1038/leu.2014.72. Epub 2014 Feb 17.
8
Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM. Venetoclax 单药治疗对低甲基化药物难治性继发性 AML 且高表达 BCL-2 和/或 BIM 患者具有持久缓解作用。
Eur J Haematol. 2019 May;102(5):437-441. doi: 10.1111/ejh.13218. Epub 2019 Feb 28.
9
BCL-2 inhibition in AML: an unexpected bonus?BCL-2 抑制在 AML 中的作用：意外之喜？
Blood. 2018 Sep 6;132(10):1007-1012. doi: 10.1182/blood-2018-03-828269. Epub 2018 Jul 23.
10
Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia.Voruciclib 通过抑制 CDK9 与 Bcl-2 选择性抑制剂 venetoclax 协同增强急性髓系白血病临床前模型中的细胞死亡。
Signal Transduct Target Ther. 2020 Feb 26;5(1):17. doi: 10.1038/s41392-020-0112-3.

引用本文的文献

1
Phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in older patients with newly diagnosed acute myeloid leukemia.西达本胺联合CAG及维奈克拉-阿扎胞苷治疗新诊断老年急性髓系白血病的2期研究
Front Immunol. 2025 Feb 26;16:1525110. doi: 10.3389/fimmu.2025.1525110. eCollection 2025.
2
Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non-low-risk AML.GIMEMA AML1718研究的安全性导入期及第一部分：维奈托克联合FLAI方案用于非低危急性髓系白血病的诱导治疗
Blood Adv. 2025 May 27;9(10):2542-2552. doi: 10.1182/bloodadvances.2024014901.
3
Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group.
来自CETLAM组的1034例急性髓系白血病患者接受强化风险适应性治疗后的不同现实生活结局。
Blood Cancer J. 2025 Jan 11;15(1):4. doi: 10.1038/s41408-024-01205-5.